Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Spruce Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SPRB
Nasdaq
8731
http://www.sprucebiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Spruce Biosciences Inc
Spruce Biosciences to Participate in May Investor Conferences
- May 1st, 2024 8:05 pm
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
- Apr 30th, 2024 8:05 pm
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
- Apr 22nd, 2024 8:05 pm
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
- Mar 27th, 2024 4:00 pm
Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)
- Mar 23rd, 2024 12:47 pm
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
- Mar 21st, 2024 2:20 pm
Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price
- Mar 16th, 2024 12:59 pm
Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks
- Mar 13th, 2024 9:33 pm
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
- Mar 13th, 2024 8:08 pm
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
- Mar 13th, 2024 8:01 pm
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Jan 30th, 2024 9:05 pm
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
- Jan 22nd, 2024 1:00 pm
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
- Jan 5th, 2024 1:00 pm
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
- Jan 4th, 2024 1:00 pm
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Nov 13th, 2023 9:05 pm
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
- Nov 2nd, 2023 8:05 pm
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
- Oct 18th, 2023 12:00 pm
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 28th, 2023 8:00 pm
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
- Aug 14th, 2023 8:00 pm
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
- Jul 24th, 2023 4:00 pm
Scroll